(P-308) Penetration Rate of Anti-tnf Biosimilars in Hospitals in France: 5 Years Status

Background: Since the fall of anti-TNF patents in Europe, France has opened its market to competition. Penetration rates between products seem to be very different.

Objectives: The objective of this study is to investigate the evolution of the market shares of biological drugs and their biosimilars.

Methods: We conducted a multi-center, retrospective and observational study between January 1, 2015 and April 1, 2020, based on the national uniform hospital discharge database, for its pharmaceutical component. It allowed us to study the sales of infliximab, etanercept and adalimumab, both originator drugs and biosimilars, in France.

Results: The hospital penetration rate of anti-TNF biosimilars in France is in 2020: 76% for infliximab, 74% for etanercept and 77% for adalimumab. In 2020, INFLECTRA® is REMICADE®'s best-selling competitor with 41% of the sales, ERELZI® is ENBREL®'s best-selling competitor with 57% of the sales and AMGEVITA® is HUMIRA®'s best-selling competitor with 64% of the sales. We observe that infliximab biosimilars pass the 50% use threshold after 3 years of commercialization, etanercept biosimilars after 2 years of commercialization and adalimumab biosimilars after 1 year of commercialization.

Conclusions: This study shows that the market is dynamic and the penetration rate in France of anti-TNF biosimilars at 5 years from market entry is close to the national target of 80% set for 2022.